Christophe Depre from Carmel, IN, age 57

Pdja1, A Cardiac Specific Gene, Corresponding Proteins, And Uses Thereof
view source
US Patent:

7803908, Sep 28, 2010
Filed:

Mar 1, 2006
Appl. No.:

11/365484
Inventors:

Christophe Depre - New York NY, US
Stephen F. Vatner - New York NY, US
Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick NJ
International Classification:

C07K 1/00
US Classification:

530350, 530300, 536 231
Abstract:

The present invention provides novel nucleic acid and protein sequences for methods and compositions for treating, screening, and diagnosing cardiovascular disease and methods for using these genes and gene products for prevention of cardiac cell death and prevention of cardiac tissue damage resulting from ischemic events in cardiac tissue, as well as other tissue that is subject to damage resulting from an ischemic event. The genes, gene products and agents of the invention are also useful for treating other related clinical or coronary events such as angina, myocardial infarct (MI), and stroke, for monitoring the effectiveness of their treatment, and for drug development. The genes, gene products and agents of the present invention are also provided as pharmaceutical compositions for treatment of cardiovascular disease, ischemic heart disease, myocardial infarct and related conditions. Kits are also provided for the diagnosis, treatment and prognosis of cardiac diseases and related conditions.

Pdja1, A Cardiac Specific Gene, Corresponding Proteins, And Uses Thereof
view source
US Patent:

20040009513, Jan 15, 2004
Filed:

May 2, 2003
Appl. No.:

10/429223
Inventors:

Christophe Depre - New York NY, US
Stephen Vatner - New York NY, US
International Classification:

C12Q001/68
C07H021/04
C12P021/06
C12N009/20
A61K048/00
C12N005/06
US Classification:

435/006000, 435/069100, 435/198000, 435/320100, 435/325000, 514/044000, 536/023200
Abstract:

The present invention provides novel nucleic acid and protein sequences for methods and compositions for treating, screening, and diagnosing cardiovascular disease and methods for using these genes and gene products for prevention of cardiac cell death and prevention of cardiac tissue damage resulting from ischemic events in cardiac tissue, as well as other tissue that is subject to damage resulting from an ischemic event. The genes, gene products and agents of the invention are also useful for treating other related clinical or coronary events such as angina, myocardial infarct (MI), and stroke, for monitoring the effectiveness of their treatment, and for drug development. The genes, gene products and agents of the present invention are also provided as pharmaceutical compositions for treatment of cardiovascular disease, ischemic heart disease, myocardial infarct and related conditions. Kits are also provided for the diagnosis, treatment and prognosis of cardiac diseases and related conditions.

Pdja1, A Cardiac Specific Gene, Corresponding Proteins, And Uses Thereof
view source
US Patent:

20110124714, May 26, 2011
Filed:

Aug 31, 2010
Appl. No.:

12/807237
Inventors:

Christophe Depre - New York NY, US
Stephen F. Vatner - New York NY, US
International Classification:

A61K 31/7088
C07H 21/00
C07H 21/04
A61P 9/00
A61P 9/10
US Classification:

514 44 R, 536 235
Abstract:

The present invention provides novel nucleic acid and protein sequences for methods and compositions for treating, screening, and diagnosing cardiovascular disease and methods for using these genes and gene products for prevention of cardiac cell death and prevention of cardiac tissue damage resulting from ischemic events in cardiac tissue, as well as other tissue that is subject to damage resulting from an ischemic event. The genes, gene products and agents of the invention are also useful for treating other related clinical or coronary events such as angina, myocardial infarct (MI), and stroke, for monitoring the effectiveness of their treatment, and for drug development. The genes, gene products and agents of the present invention are also provided as pharmaceutical compositions for treatment of cardiovascular disease, ischemic heart disease, myocardial infarct and related conditions. Kits are also provided for the diagnosis, treatment and prognosis of cardiac diseases and related conditions.